Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

Activation of the A3 adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils

(2010) Dharini van der Hoeven et al.   BIOCHEMICAL PHARMACOLOGY

Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins

(2010) A. Schmiedl et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Sitagliptin (MK0431) Inhibition of Dipeptidyl Peptidase IV Decreases Nonobese Diabetic Mouse CD4+ T-Cell Migration Through Incretin-Dependent and -Independent Pathways

(2010) S.-J. Kim et al.   DIABETES

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

(2010) M. Sauve et al.   DIABETES

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2010) Joshua J Neumiller et al.   PHARMACOTHERAPY

Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis

(2010) M. Kronlage et al.   Science Signaling

Tumor Necrosis Factor-α Potentiates RhoA-Mediated Monocyte Transmigratory Activity In Vivo at a Picomolar Level

(2009) Sunny Lim et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

(2009) David J Grieve et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ambient Air Pollution Exaggerates Adipose Inflammation and Insulin Resistance in a Mouse Model of Diet-Induced Obesity

(2009) Qinghua Sun et al.   CIRCULATION

Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions

(2009) Siegfried Ansorge et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

(2009) Dirk Reinhold et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

(2009) Hongbin Liu et al.   JOURNAL OF ENDOCRINOLOGY

Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies

(2009) Kiwon Ban et al.   Journal of the American Society of Hypertension

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites

(2009) F. K. Swirski et al.   SCIENCE

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

(2009) Roger Yazbeck et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP

(2008) Brian D. Green et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

(2008) R CHRISTOPHER et al.   CLINICAL THERAPEUTICS

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

(2008) P COVINGTON et al.   CLINICAL THERAPEUTICS

Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice

(2008) Yusuke Moritoh et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Stromal cell-derived factors 1α and 1β, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8

(2008) Katerina Ajami et al.   FEBS LETTERS

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE

DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis

(2007) Dirk Reinhold   Frontiers in Bioscience-Landmark

DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes

(2007) Carolyn et al.   Frontiers in Bioscience-Landmark